The bill requires the Executive Office of Health and Human Services to submit a quarterly report detailing the projected total costs for pharmaceutical pipeline drugs anticipated to be available for use within the next fiscal year. Specifically, it focuses on drugs identified by the executive office, with a report due for the period from October 1, 2024, to September 30, 2025. The report will include an estimated expenditure of approximately $18.9 million for all MassHealth members, which marks a significant increase from a previous estimate of $8.4 million due to the addition of new pipeline market entries, including novel cell therapies and a new treatment for acute pain. Additionally, the bill includes a new contact email for inquiries related to the report, specifically Sarah.Nordberg@mass.gov. This change aims to streamline communication regarding the report and its findings. Overall, the bill emphasizes the importance of transparency and fiscal planning in the management of pharmaceutical costs within the MassHealth program.